Serina Therapeutics Inc Total Liabilities
Serina Therapeutics Inc total liabilities. Based on the latest financial reports, Serina Therapeutics Inc (SER) has total liabilities worth $10.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Serina Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Serina Therapeutics Inc (2016–2024)
Total liabilities of Serina Therapeutics Inc from 2016 to 2024. This chart illustrates how Serina Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Serina Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Serina Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Leeuwin Metals Ltd
AU:LM1
|
Australia | AU$2.08 Million |
|
BMS Celik Hasir Sanayi ve Ticaret AS
IS:BMSCH
|
Turkey | TL869.65 Million |
|
Aqua Corporation Public Company Limited
BK:AQUA
|
Thailand | ฿3.40 Billion |
|
CHARWOOD ENERGY EO -01
F:L5Q
|
Germany | €13.81 Million |
|
Infoline Tec Holdings Bhd
KLSE:0253
|
Malaysia | RM24.97 Million |
|
Beamr Imaging Ltd. Ordinary Share
NASDAQ:BMR
|
USA | $1.06 Million |
|
Seres Therapeutics Inc
NASDAQ:MCRB
|
USA | $67.05 Million |
|
Theta Edge Bhd
KLSE:9075
|
Malaysia | RM43.41 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Serina Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SER asset base.
Liquidity & Leverage Metrics
Serina Therapeutics Inc Total Liabilities Ratios Explained
Serina Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.98 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Serina Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Serina Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Serina Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.22 Million | -84.94% |
| 2023-12-31 | $41.26 Million | +100.73% |
| 2022-12-31 | $20.56 Million | +36.78% |
| 2021-12-31 | $15.03 Million | +61.24% |
| 2020-12-31 | $9.32 Million | +93.18% |
| 2019-12-31 | $4.83 Million | +97.75% |
| 2018-12-31 | $2.44 Million | +85.98% |
| 2017-12-31 | $1.31 Million | -94.87% |
| 2016-12-31 | $25.60 Million | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more